The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs

New antiviral drugs are needed for the treatment of cytomegalovirus (CMV) infections, particularly in immunocompromised patients. These studies evaluated the in vitro and in vivo activity of the non-nucleosidic CMV inhibitor, BAY 38-4766, against guinea pig cytomegalovirus (GPCMV). Plaque reduction...

Full description

Saved in:
Bibliographic Details
Main Authors: Schleiss, Mark R., Bernstein, David I., McVoy, Michael A., Stroup, Greg, Bravo, Fernando, Creasy, Blaine, McGregor, Alistair, Henninger, Kristin, Hallenberger, Sabine
Format: Artigo
Language:Inglês
Published: 2005
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2768478/
https://ncbi.nlm.nih.gov/pubmed/15652969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2004.09.004
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items